Cargando…
Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis
INTRODUCTION: Individualisation of rheumatoid arthritis (RA) treatment needs to take account of individual patients’ preferences to increase patient-centeredness in treatment decisions. The aim of this study was to identify patient-relevant treatment attributes to consider when individualising treat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873051/ https://www.ncbi.nlm.nih.gov/pubmed/34655004 http://dx.doi.org/10.1007/s10067-021-05961-8 |
_version_ | 1784657379159179264 |
---|---|
author | Bywall, Karin Schölin Esbensen, Bente Appel Lason, Marta Heidenvall, Marie Erlandsson, Inger Johansson, Jennifer Viberg |
author_facet | Bywall, Karin Schölin Esbensen, Bente Appel Lason, Marta Heidenvall, Marie Erlandsson, Inger Johansson, Jennifer Viberg |
author_sort | Bywall, Karin Schölin |
collection | PubMed |
description | INTRODUCTION: Individualisation of rheumatoid arthritis (RA) treatment needs to take account of individual patients’ preferences to increase patient-centeredness in treatment decisions. The aim of this study was to identify patient-relevant treatment attributes to consider when individualising treatment for patients with RA. METHOD: Patients with RA in Sweden were invited to rank the most important treatment attributes in an online survey (April to May 2020). Semi-structured interviews were conducted (October to November 2020) to further identify and frame potential attributes for shared decision-making. The interviews were audio-recorded, transcribed and analysed using thematic framework analysis. Patient research partners and rheumatologists supported the selection and framing of the treatment attributes across the assessment. RESULTS: The highest ranked attributes (N = 184) were improved functional capacity, reduced inflammation, reduced pain and fatigue and the risk of getting a severe side effect. The framework analysis revealed two overarching themes for further exploration: treatment goals and side effects. ‘Treatment goals’ emerged from functional capacity, revealing two dimensions: physical functional capacity and psychosocial functional capacity. ‘Side effects’ revealed that mild and severe side effects were the most important to discuss in shared decision-making. CONCLUSIONS: Functional capacity (physical and psychosocial) and potential side effects (mild and severe) are important treatment attributes to consider when individualising RA treatment. Future research should assess how patients with RA weigh benefits and risks against each other, in order to increase patient-centeredness early on the treatment trajectory. |
format | Online Article Text |
id | pubmed-8873051 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-88730512022-03-02 Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis Bywall, Karin Schölin Esbensen, Bente Appel Lason, Marta Heidenvall, Marie Erlandsson, Inger Johansson, Jennifer Viberg Clin Rheumatol Original Article INTRODUCTION: Individualisation of rheumatoid arthritis (RA) treatment needs to take account of individual patients’ preferences to increase patient-centeredness in treatment decisions. The aim of this study was to identify patient-relevant treatment attributes to consider when individualising treatment for patients with RA. METHOD: Patients with RA in Sweden were invited to rank the most important treatment attributes in an online survey (April to May 2020). Semi-structured interviews were conducted (October to November 2020) to further identify and frame potential attributes for shared decision-making. The interviews were audio-recorded, transcribed and analysed using thematic framework analysis. Patient research partners and rheumatologists supported the selection and framing of the treatment attributes across the assessment. RESULTS: The highest ranked attributes (N = 184) were improved functional capacity, reduced inflammation, reduced pain and fatigue and the risk of getting a severe side effect. The framework analysis revealed two overarching themes for further exploration: treatment goals and side effects. ‘Treatment goals’ emerged from functional capacity, revealing two dimensions: physical functional capacity and psychosocial functional capacity. ‘Side effects’ revealed that mild and severe side effects were the most important to discuss in shared decision-making. CONCLUSIONS: Functional capacity (physical and psychosocial) and potential side effects (mild and severe) are important treatment attributes to consider when individualising RA treatment. Future research should assess how patients with RA weigh benefits and risks against each other, in order to increase patient-centeredness early on the treatment trajectory. Springer International Publishing 2021-10-15 2022 /pmc/articles/PMC8873051/ /pubmed/34655004 http://dx.doi.org/10.1007/s10067-021-05961-8 Text en © The Author(s) 2021, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Bywall, Karin Schölin Esbensen, Bente Appel Lason, Marta Heidenvall, Marie Erlandsson, Inger Johansson, Jennifer Viberg Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis |
title | Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis |
title_full | Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis |
title_fullStr | Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis |
title_full_unstemmed | Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis |
title_short | Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis |
title_sort | functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873051/ https://www.ncbi.nlm.nih.gov/pubmed/34655004 http://dx.doi.org/10.1007/s10067-021-05961-8 |
work_keys_str_mv | AT bywallkarinscholin functionalcapacityvssideeffectstreatmentattributestoconsiderwhenindividualisingtreatmentforpatientswithrheumatoidarthritis AT esbensenbenteappel functionalcapacityvssideeffectstreatmentattributestoconsiderwhenindividualisingtreatmentforpatientswithrheumatoidarthritis AT lasonmarta functionalcapacityvssideeffectstreatmentattributestoconsiderwhenindividualisingtreatmentforpatientswithrheumatoidarthritis AT heidenvallmarie functionalcapacityvssideeffectstreatmentattributestoconsiderwhenindividualisingtreatmentforpatientswithrheumatoidarthritis AT erlandssoninger functionalcapacityvssideeffectstreatmentattributestoconsiderwhenindividualisingtreatmentforpatientswithrheumatoidarthritis AT johanssonjenniferviberg functionalcapacityvssideeffectstreatmentattributestoconsiderwhenindividualisingtreatmentforpatientswithrheumatoidarthritis |